霍奇金淋巴瘤和其他血液恶性瘤中的免疫检查点分子
Mohamed Nazem Alibrahim1, Antonino Carbone2, Noor Alsaleh3
1Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig 44519, Egypt.
Cancers
|July 29, 2025
概括
免疫检查点抑制剂 (ICI) 在血液癌症中表现出不同的疗效. 结合ICI与其他疗法和生物标志物选择的策略对于克服非霍奇金淋巴瘤,急性髓性白血病和多发性髓瘤的耐药性至关重要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
背景情况:
- 免疫检查点 (PD-1/PD-L1,CTLA-4,LAG-3,TIM-3,TIGIT) 调节抗瘤免疫力,并且是血液恶性瘤的目标.
- 经典霍奇金淋巴瘤 (HL) 对免疫检查点抑制剂 (ICI) 的反应很好,原因是基因因素,如染色体9p24.1放大.
- 非霍奇金淋巴瘤 (NHL),急性髓性白血病 (AML) 和多发性骨髓瘤 (MM) 对ICI表现出不一致和适度的反应.
研究的目的:
- 分析各种血液性恶性瘤对免疫检查点抑制剂 (ICI) 的差异反应.
- 确定导致NHL,AML和MM中ICI耐药性的因素.
- 探索未来的策略,以提高免疫疗法在血液癌症的疗效.
主要方法:
- 关于ICI在HL,NHL,AML和MM中的疗效现有文献的审查.
- 分析瘤微环境特征和影响ICI反应的遗传变化.
- 对抗性机制的评估,包括内在的瘤因素和外在的免疫抑制因素.
主要成果:
- 根据免疫微环境异质性和PD-L1表达,NHL的结果有所不同.
- AML对单一治疗的反应有限,但在特定子集中使用低甲基化剂组合的结果有所改善.
- 许多MM试验在很大程度上失败了,可能是由于遗传多态性和免疫抑制性骨髓微环境.
结论:
- 血液性恶性瘤中对ICI的原发性和获得性耐药性是由内在瘤因素和外在免疫抑制机制驱动的.
- 未来的战略应侧重于组合疗法 (双检查点封锁,表观遗传调制,TME重编程) 和生物标志物驱动的患者选择.
- 针对各种血液性恶性瘤,需要量身定制的,精确的免疫治疗方法,以克服耐药性并改善患者的治疗结果.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Cytotoxic T Cells-mediated Immune Response
2.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.1K
Lymphoid Cells and Tissues
1.5K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.5K
B Cell Activation and Differentiation
5.9K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
5.9K


